Merck Serono and partner Newron Pharmaceuticals SpA have initiated the SETTLE study to evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as an add-on therapy to levodopa, in mid- to late-stage Parkinson’s disease patients. The SETTLE study is one of the Phase III trials for a development program designed to support an application for marketing authorization. SETTLE is a six-month, randomized, double-blind, placebo-controlled trial that includes more t...